Drug Profile
BVA 501
Alternative Names: BVA-501Latest Information Update: 03 Nov 2022
Price :
$50
*
At a glance
- Originator Biovista
- Class Antineoplastics
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Glioblastoma; Malignant melanoma; Thyroid cancer
Most Recent Events
- 25 Aug 2022 Preclinical development is ongoing in USA (Biovista pipeline, August 2022)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma in USA